This is a working overview of actin-binding motif, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
It was certainly one of the worst medical mistakes, a major mistake." Upon its release in 1995, OxyContin was hailed as a medical breakthrough, a long-lasting narcotic that could help patients with moderate to severe pain. The drug became a blockbuster and has reportedly generated some US$35 billion in revenue for Purdue.
It has been the world's largest producer of coffee for the last 150 years and is the world's largest producer of sugarcane, soy, coffee and oranges; is one of the top five producers of maize, cotton, lemon, tobacco, pineapple, banana, beans, coconut, watermelon and papaya; and is one of the top 10 world producers of cocoa, cashew, mango, rice, tomato, sorghum, tangerine, avocado, persimmon, and guava, among others. Regarding livestock, it is one of the five largest producers of chicken meat, beef, pork and cow's milk in the world. In the mining sector, Brazil is among the largest producers of iron ore, copper, gold, bauxite, manganese, tin, niobium, and nickel. In terms of precious stones, Brazil is the world's largest producer of amethyst, topaz, agate and one of the main producers of tourmaline, emerald, aquamarine, garnet and opal. The country is a major exporter of soy, iron ore, pulp (cellulose), maize, beef, chicken meat, soybean meal, sugar, coffee, tobacco, cotton, orange juice, footwear, airplanes, cars, vehicle parts, gold, ethanol and semi-finished iron, among other products. Brazil is the world's 24th-largest exporter and 26th-largest importer as of 2021. China is its largest trading partner, accounting for 32% of the total trade. Other large trading partners include the United States, Argentina, the Netherlands and Canada. Its automotive industry is the eighth-largest in the world. In the food industry, Brazil was the second-largest exporter of processed foods in the world in 2019.
=== U.S. News & World Report's Best High Schools === Since 2007, U.S. News & World Report has ranked high schools in PGCPS among the Best High Schools in America. High Point High School, Northwestern High School, and Eleanor Roosevelt High School have been recognized as Silver Medal Schools.
There's no way it (KFC) could have grown as it did without the Collectramatic. Stores were doing about $200,000 a year in sales on average with the pots...but they could never have done the $900,000 a year it became without Win's fryer. He (Shelton) helped set the stage for that with true engineering thinking. Although a number of franchisees bought the Collectramatic, which had the support of Colonel Sanders from 1970 onwards, John Y. Brown Jr. had given tacit approval to franchisees to exclusively use the older L S Hartzog fryer, saying "Though those old pots were damn dangerous, at least we knew they worked! I was mostly afraid these new fryers would break down in the middle of business." Brown warned franchisees that they were in violation of their contract if they used the Collectramatic. Brown held his ground on the issue until he learned that his father, John Y. Brown Sr., who owned multiple KFC franchises, was successfully using the Collectramatic in every franchise he owned. The issue was eventually resolved after Heublein purchased KFC, acquired Hartzog and nullified the contract. The Collectramatic has been an approved pressure fryer for KFC from 1972 onwards. From 2013 onwards, KFC has been transitioning from using Collectramatic cookers to pressure fryers produced by Henny Penny, which supplies KFC with various equipment. The 'Velocity' series of pressure fryers includes increased load capacity, automatic oil filtration and increased oil longevity.
Sources: en.wikipedia.org
In the phosphatidylinositol signal pathway, the extracellular signal molecule binds with the G-protein receptor (Gq) on the cell surface and activates phospholipase C, which is located on the plasma membrane. The lipase hydrolyzes PIP2 into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds with the IP3 receptor in the membrane of the smooth endoplasmic reticulum and mitochondria to open Ca2+ channels. DAG helps activate protein kinase C (PKC), which phosphorylates many other proteins, changing their catalytic activities, leading to cellular responses. The effects of Ca2+ are also remarkable: it cooperates with DAG in activating PKC and can activate the CaM kinase pathway, in which calcium-modulated protein calmodulin (CaM) binds Ca2+, undergoes a change in conformation, and activates CaM kinase II, which has unique ability to increase its binding affinity to CaM by autophosphorylation, making CaM unavailable for the activation of other enzymes. The kinase then phosphorylates target enzymes, regulating their activities. The two signal pathways are connected together by Ca2+-CaM, which is also a regulatory subunit of adenylyl cyclase and phosphodiesterase in the cAMP signal pathway.
As research on nuclear fission progressed in early 1939, Edwin McMillan at the Berkeley Radiation Laboratory of the University of California, Berkeley decided to run an experiment bombarding uranium using the powerful 60-inch (1.52 m) cyclotron that had recently been built at the university. The purpose was to separate the various fission products produced by the bombardment by exploiting the enormous force that the fragments gain from their mutual electrical repulsion after fissioning. Although he did not discover anything of note from this, McMillan did observe two new beta decay half-lives in the uranium trioxide target itself, which meant that whatever was producing the radioactivity had not violently repelled each other like normal fission products. He quickly realized that one of the half-lives closely matched the known 23-minute decay period of uranium-239, but the other half-life of 2.3 days was unknown. McMillan took the results of his experiment to chemist and fellow Berkeley professor Emilio Segrè to attempt to isolate the source of the radioactivity. Both scientists began their work using the prevailing theory that element 93 would have similar chemistry to rhenium, but Segrè rapidly determined that McMillan's sample was not at all similar to rhenium. Instead, when he reacted it with hydrogen fluoride (HF) with a strong oxidizing agent present, it behaved much like members of the rare earths.
== Neurodegeneration == Inhibition of Hsp90 leads to Hsp70 and Hsp40 upregulation, which can channel misfolded protein for proteasome degradation, which can potentially inhibit the progression of neurodegenerative diseases. For example, Hsp70 overexpression in human neuroglioma cells transfected with mutant alpha-synuclein led to 50% less oligomeric alpha-synuclein species, pointing towards the possibility that increasing its expression could diminish the spread of Parkinson's disease. Similarly, Hsp70 overexpression suppressed poly-Q dependent aggregation and neurodegeneration in cell cultures, yeast, fly, and mouse models, and deletion of hsp70 increased the size of polyQ inclusion bodies, suggesting that increasing its expression could help to prevent Huntington's disease. Similarly, reductions in Hsp70 have been shown in transgenic mouse models of ALS and patients with sporadic ALS. Lastly, increased expression or activity of Hsp70 has been proposed as a method to prevent the progression of Alzheimer's disease, because knock down of Hsp70 promoted A-beta toxicity, and Hsp70 was shown to promote tau stability, while Hsp70 levels are decreased in tauopathies like Alzheimer's disease. Given the complex interplay between the different chaperone proteins, therapeutic development in this field is aimed at investigating how the chaperone network as a whole can be manipulated and the effect of this manipulation on the progression of neurodegenerative disease, but the balance of Hsp70 and Hsp90 levels appears to be central in this pathophysiology.
Sources: en.wikipedia.org
Tertiary structure may give way to the formation of quaternary structure in some proteins, which usually involves the "assembly" or "coassembly" of subunits that have already folded; in other words, multiple polypeptide chains could interact to form a fully functional quaternary protein.
Some statins, including atorvastatin (Lipitor), lovastatin (Mevacor), and simvastatin (Zocor, Simlup, Simcor, Simvacor) In contrast, pravastatin (Pravachol), fluvastatin (Lescol), and rosuvastatin (Crestor) are unaffected by grapefruit. Anti-arrhythmics including amiodarone (Cordarone), dronedarone (Multaq), quinidine (Quinidex, Cardioquin, Quinora), disopyramide (Norpace), propafenone (Rythmol) and carvedilol (Coreg) Amlodipine: Grapefruit increases the available amount of the drug in the blood stream, leading to an unpredictable increase in antihypertensive effects. Anti-migraine drugs ergotamine (Cafergot, Ergomar), amitriptyline (Elavil, Endep, Vanatrip) and nimodipine (Nimotop) Erectile dysfunction drugs sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra) Acetaminophen (also known as paracetamol, brand name Tylenol) concentrations increase in the blood of mice when they consume white and pink grapefruit juice, with the white juice acting faster. "The bioavailability of paracetamol was significantly reduced following multiple GFJ administration" in mice and rats. This suggests that repeated intake of grapefruit juice reduces the efficacy and bioavailability of acetaminophen/paracetamol in comparison with a single dose of grapefruit juice, which conversely increases the efficacy and bioavailability of acetaminophen/paracetamol.
== Expression/Production systems == Different organisms may be used to express a gene's target protein, and the expression vector used will therefore have elements specific for use in the particular organism. The most commonly used organism for protein production is the bacterium Escherichia coli. However, not all proteins can be successfully expressed in E. coli, or be expressed with the correct form of post-translational modifications such as glycosylations, and other systems may therefore be used.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.